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Abstract: 
Cancer cells must rewrite their ‘‘internal code’’ to satisfy the demand for growth and proliferation. 
Such changes are driven by a combination of genetic (e.g., genes’ mutations) and non-genetic 
factors (e.g., tumour microenvironment) that result in an alteration of cellular metabolism. 
For this reason, understanding the metabolic and genomic changes of a cancer cell can provide 
useful insight on cancer progression and survival outcomes. 
 
In our work, we present a computational framework that uses patient-specific data to investigate 
cancer metabolism and provide personalised survival predictions and cancer development 
outcomes. The proposed model integrates patient-specific multi-omics data (i.e., genomic, 
metabolomic and clinical data) into a metabolic model of cancer to produce a list of metabolic 
reactions affecting cancer progression. 
Quantitative and predictive analysis, through survival analysis and machine learning techniques, 
is then performed on the list of selected reactions. 
 
Since our model performs an analysis of patient-specific data, the outcome of our pipeline 
provides a personalised prediction of survival outcome and cancer development based on a 
subset of identified multi-omics features (genomic, metabolomic and clinical data).  
 
In particular, our work aims to develop a computational pipeline for clinicians that relates the 
omic profile of each patient to their survival probability, based on a combination of machine 
learning and metabolic modelling techniques. The model provides patient-specific predictions on 
cancer development and survival outcomes towards the development of personalised medicine.   





Problem: Understanding Cancer Progression
Cancer cells must rewrite their “internal code” in order to satisfy the demand for growth and proliferation.
Such changes result in an alteration of cellular metabolism and they are driven by a combination of genetic
factors (e.g., genes’ mutations) and non-genetic factors (e.g., tumour microenvironment).
For this reason, understanding the metabolic and genomic changes of a cancer cell can provide useful insight
on cancer progression and survival outcomes.
Proposed Solution: Computational Model of Cancer
We present a computational framework that uses patient-specific data to investigate breast cancer
metabolism and provide personalised survival predictions and cancer development outcomes.
The pipeline of the proposed model constists of four main steps:
(a) Multi-omic data (i.e., genomic, metabolomic and clinical data) are collected from publicly available
cancer repositories, such as The Cancer Genome Atlas and cBioPortal (Figure 1(a));
(b) The collected data are integrated into a metabolic model of breast cancer to produce a list of metabolic
reactions affecting cancer progression (Figure 1(b));
(c) Quantitative and predictive analysis, through survival analysis and machine learning techniques, is
then performed on the list of selected reactions (Figure 1(c));
(d) Since our model performs an analysis of patient-specific data, the outcome of our pipeline provides a
personalised prediction of survival outcome and cancer development based on a subset of identified
multi-omics features (genomic, metabolomic and clinical data (Figure 1(d)).
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Figure 1. Pipeline of the proposed methodology for turning a metabolic model of cancer cell into a patient-
specific tool for survival prediction and cancer development probability.
Results: Predicting Survival Outcomes
Patients are stratified in high/low-risk groups based on their prognostic index, a numeric value that is used to
determine the status of the cancer. The predictive model of breast cancer can be used to produce two main
outcomes:
• Selection of cancer-related metabolic reactions. 5 reactions resulted higher in the high-risk patients
than in the low-risk patients. All the five reactions are involved in the fatty acids synthesis, which is
strictly related to cancer (Figure 2(a)).
• Survival Probability Prediction The correlation between the selected fluxes and survival outcomes is
used to build the predictive model (Figure 2(b)).
(a) (b)
Figure 2. (a) Top-5 differentially active reactions in high-risk and low-risk patients.(b) Kaplan-Meier valida-
tion plot. We used the discovery Metabric set to train our model and to obtain a threshold t for stratifying the
patients in high/low-risk groups based on their prognostic index. Such threshold was then used to predict the
risk group of an independent dataset (validation Metabric set), never “seen” in the training phase. Figure (b)
shows the obtained KM curve.
Methodology
1. A computational model of cancer
metabolism is developed to investigate
the reactions taking place in the cancer cell.
2. Flux Balance Analysis is then applied to
identify the reactions affecting cancer pro-
gression.
3. Machine Learning and Statistical Tech-
niques are run to uncover the relation between
the selected reactions and patients survival.
4. Survival Analysis is finally applied to clas-
sify the patients into high-risk and low-risk
groups, based on their omic information.
Conclusions
• We present a patient-specific metabolic
model model of breast cancer to predict sur-
vival outcomes.
• Machine Learning techniques are used to in-
vestigate and analyse the metabolic reactions
affecting breast cancer development.
• Multi-omics data were used to develop the
model, providing a better predictions on
cancer development and survival outcomes







Personalised test to predict the probability of 
developing breast cancer
Machine Learning Model 
Figure 3. Main outcome of the proposed model.
Starting from patient-specific data, our model
uses machine learning techniques to predict the
probability of developing breast cancer and provides
patient-specific survival outcomes.
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